Health

Surging demand, clinical-quality targets, and skyrocketing input costs are squeezing GCC healthcare budgets. Best-in-class procurement—clean-sheet drug costing, multi-vendor device RFPs, and outcome-based service contracts—liberates the cash hospitals need for digital patient journeys, AI diagnostics, and centres of excellence. Providers that master their supply economics today will deliver tomorrow’s value-based care without margin pain. 

 

Governments are doubling down on localisation. Saudi Arabia’s National Industrial Strategy calls for domestic manufacturing of generics, injectables, and disposables, while the UAE’s Pharma Valley initiative ties market access to in-country value. Embedding local-content clauses in tenders, co-investing with regional producers, and training national pharmacists turn compliance into a competitive edge—securing preferential reimbursements, faster product registrations, and reputational lift. 

 

Supply-chain resilience is mission-critical after pandemic shortages and global logistics shocks. Leading health systems dual-source high-value SKUs, build regional cold-chain hubs, and deploy AI demand-sensing to anticipate seasonal surges. When these tactics sit inside a disciplined operating model—digital PO approvals, clear RACIs, and live KPI dashboards—procurement moves from firefighting to clinically driven, cost-smart decision-making.